A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

Updated on 23 November 2020
illicit drug


To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of CD-LD-experienced subjects with Parkinson's disease (PD) who have motor fluctuations.



Condition Narcolepsy
Clinical Study IdentifierTX228693
Last Modified on23 November 2020


Yes No Not Sure

Inclusion Criteria

Male or female subjects diagnosed at age ≥ 40 years with PD, consistent with the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria and who are being treated with stable regimens of CD-LD but experiencing motor fluctuations
Able to provide written informed consent prior to the conduct of any study-specific procedures
Female subjects of childbearing potential must have a negative urine pregnancy test at Screening Visit
Negative urine screen for drugs of abuse and negative alcohol breath test at Screening
Hoehn and Yahr Stages 1, 2, 3, or 4 in the "On" state (part of Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale [MDS-UPDRS] Part III) Agrees to use a medically acceptable method of contraception throughout the study and for 6 weeks after completing the study. Medically acceptable methods of contraception that may be used by the subject and/or partner include but are not limited to: abstinence, oral contraception, NuvaRing or transdermal systems, diaphragm with vaginal spermicide, intrauterine device, condom and partner using vaginal spermicide, surgical sterilization (6 months), progestin implant or injection, or postmenopausal female (no menstrual period for ˃ 2 years) or vasectomy (˃ 6 months)
Montreal Cognitive Assessment (MoCA) score ≥ 24 at Screening Visit in "On" state
Able to differentiate "On" state from "Off" state as determined by at least 75% concordance with a trained rater in "On/Off" ratings for 8 ratings over a 4-hour training period. The concordance must include at least 1 "On" and 1 "Off" rating and must be achieved within two 4-hour training sessions
Able and willing to comply with the protocol, including completion of diaries and availability for all study visits
Responsive to CD-LD therapy and currently being treated on a stable regimen with CD-LD for at least 4 weeks prior to Visit 1
At Screening, the subject has predictable "Off" periods

Exclusion Criteria

Received any investigational medications within 30 days or 5 times the half-life, whichever is longer, prior to Visit 1
Female subjects who are currently breastfeeding or lactating
Had prior neurosurgical treatment for PD or if such procedure is planned or anticipated during the study period
Allergic to any excipient in the study drugs
History of medical conditions or of a prior surgical procedure that would interfere with LD absorption, such as gastrectomy, proximal small-bowel resection, or bariatric surgery
History of upper gastrointestinal hemorrhage in patients with peptic ulcer disease within the past 5 years
History of glaucoma with intraocular pressures that are elevated despite appropriate medical management
History of seizure or epilepsy and experienced at least 1 seizure during the past 12 months or has not been compliant with medically recommended therapy or visits
History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias that are not controlled with medical and/or surgical interventions. A recent (≤ 12 months) history of myocardial infarction with secondary arrhythmias is exclusionary regardless of the therapeutic control
History of neuroleptic malignant syndrome or of nontraumatic rhabdomyolysis
Liver enzyme values ≥ 2.5 times the upper limit of normal; or history of severe hepatic impairment
Serum creatinine level ≥ 1.75 times the upper limit of normal; or requires dialysis at the time of Screening
Subject with a history of malignant melanoma or with a suspicious undiagnosed skin lesion which in the opinion of the investigator could be melanoma
History of drug or alcohol abuse within the 12 months prior to Screening
Received within 4 weeks of Screening or planning to take during participation in the clinical study
> Any doses of a CR CD-LD apart from a single daily bedtime dose, any doses
> of Rytary, additional CD (eg, Lodosyn) or benserazide (eg, Serazide), or
> catechol-O-methyl transferase inhibitors (entacapone or tolcapone) or
> medications containing these inhibitors (Stalevo), Nonselective monoamine
> oxidase inhibitors (MAOI), apomorphine, or antidopaminergic agents
> including antiemetics
Employees or family members of the investigator, study site, or sponsor
Subjects who have previously participated in an IPX203 study
Subjects who, in the opinion of the clinical investigator, should not participate in the study
Based on clinical assessment, subject does not adequately comprehend the terminology needed to complete the PD diary
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note